Mockingbird Society

Umoja Biopharma is a clinical-stage biotechnology company focused on transforming the field of immunotherapy through in vivo cell engineering. The company leverages its proprietary integrated technology platforms—VivoVec, RACR/CAR, and TumorTag—to create CAR-T cells directly within the patient's body, bypassing the complexities of traditional ex vivo manufacturing. Its lead candidate, UB-VV111, is an in vivo lentiviral vector targeting CD19-positive hematologic malignancies. Umoja's approach aims to provide more accessible, scalable, and effective treatments for both liquid and solid tumors. Headquartered in Seattle, the company is supported by a robust network of investors and operates its own internal manufacturing facility to accelerate clinical development.